Deaths Linked to Gene Therapy Renew Focus on Safety and Regulation
After the death of an eight-year-old child, the U.S. Food and Drug Administration has decided to lift its request to pause Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy, called Elevidys. The decision comes after
